Background CT-P13 was developed as a biosimilar product to infliximab (Remicade;), a chimeric monoclonal antibody approved in the European Union in 1999 for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. ...
The methodological implementation of the research question was complex for two reasons. First, because Remicade®is indicated for several autoimmune disorders that have primary manifestations such as joint pain and bowel inflammation but can also have secondary manifestations such as NIU. We accounted f...